Adimmune Corporation (TWSE: 4142)
Health Care · Biotechnology · TW
NT$19.20
+6.67% today · +4.6% 1Y
Adimmune Corporation (TWSE: 4142) operates in the Biotechnology industry within the Health Care sector. The company is valued at $253.10M and employs 564 people.
Over the last twelve months the share price has gained 4.6%, trading between 16.40 and 22.50.
Tweenvest scores Adimmune Corporation across four factors: quality 77/100, value 74/100. Its strongest factor is quality.
4142 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $253.10M
- Revenue (TTM)
- $43.06M
- P/E
- —
- EPS
- -0.34
- Dividend yield
- —
- Beta (5Y)
- 0.27
- 52-week high
- NT$22.50
- 52-week low
- NT$16.40
- Avg volume (3M)
- —
- Shares outstanding
- 421.51M
- Employees
- 564
- Next earnings
- —
About Adimmune Corporation
Adimmune Corporation, a Taiwanese pharmaceutical company, specializes in the production and distribution of human vaccines. Its comprehensive product portfolio includes a range of critical immunizations. Key offerings feature the quadrivalent influenza vaccine, AdimFlu-S, alongside trivalent influenza vaccines and the Influenza A (H1N1) Virus Monovalent Vaccine. The company also provides tetanus toxoid products, vital for post-injury tetanus prevention, and Japanese encephalitis vaccines. Furthermore, Adimmune supplies purified Tuberculin and extends its expertise through contract manufacturing services. Established in 1965, the company initially operated under the name Kuo Kwang Serum and Vaccine Manufacture Co., Ltd. It subsequently rebranded as Adimmune Corporation in 2001 and maintains its headquarters in Taichung, Taiwan.
- ISIN
- TW0004142005
- Founded
- 1965
- Listed since
- May 3, 2012
- Exchange
- Taiwan Stock Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Immuneering CorporationNasdaqGM: IMRX | $254.91M | $3.94 | -3.19% |
| Amarin Corporation plcNasdaqCM: AMRN | $254.11M | $12.03 | -2.59% |
| Intelligene Inc.TPEX: 7832 | $253.95M | NT$14.00 | +2.56% |
| Vicore Pharma Holding AB (publ)OM: VICO | $253.39M | Skr9.00 | -3.43% |
| Lineage Cell Therapeutics, Inc.NYSEAM: LCTX | $251.39M | $0.99 | +6.85% |
| TriSalus Life Sciences, Inc.NasdaqGM: TLSI | $249.99M | $4.06 | -6.02% |
| Zentalis Pharmaceuticals, Inc.NasdaqGM: ZNTL | $249.93M | $2.66 | +0.76% |
| HighTide Therapeutics, Inc.SEHK: 2511 | $249.35M | HK$3.43 | -2.14% |
Figures last refreshed Oct 11, 2026.